These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 10928650)

  • 1. Elimination of serum complexed prostate-specific antigen after radical retropubic prostatectomy.
    Stephan C; Jung K; Brux B; Lein M; Sinha P; Schnorr D; Loening SA
    Clin Chem Lab Med; 2000 Apr; 38(4):309-11. PubMed ID: 10928650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation.
    Stephan C; Jung K; Brux B; Lein M; Sinha P; Schnorr D; Loening SA
    Urology; 2000 Apr; 55(4):560-3. PubMed ID: 10736503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy.
    Gregorakis AK; Malovrouvas D; Stefanakis S; Petraki K; Scorilas A
    Clin Chim Acta; 2005 Jul; 357(2):196-201. PubMed ID: 15936010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
    Björk T; Schalken J; Wittjes W; Ljungberg B; Lilja H
    Prostate; 2001 Apr; 47(1):14-20. PubMed ID: 11304725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.
    Lilja H; Haese A; Björk T; Friedrich MG; Piironen T; Pettersson K; Huland E; Huland H
    J Urol; 1999 Dec; 162(6):2029-34; discussion 2034-5. PubMed ID: 10569562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy.
    Richardson TD; Wojno KJ; Liang LW; Giacherio DA; England BG; Henricks WH; Schork A; Oesterling JE
    Urology; 1996 Dec; 48(6A Suppl):40-4. PubMed ID: 8973698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy.
    Gregorakis AK; Stefanakis S; Malovrouvas D; Petraki K; Gourgiotis D; Scorilas A
    Prostate; 2008 May; 68(7):759-65. PubMed ID: 18213630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
    Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
    BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
    Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
    J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy.
    Lein M; Brux B; Jung K; Henke W; Koenig F; Stephan C; Schnorr D; Loening SA
    Eur J Clin Chem Clin Biochem; 1997 Aug; 35(8):591-5. PubMed ID: 9298348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological features of patients with biochemical recurrence after radical prostatectomy without progressive rise in serum prostate-specific antigen.
    Miyake H; Hara I; Kurahashi T; Muramaki M; Yamanaka K; Inoue TA; Fujisawa M
    Urol Int; 2006; 77(3):200-4. PubMed ID: 17033205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and complications of radical prostatectomy in patients with PSA <10 ng/ml: comparison between the retropubic, perineal and laparoscopic approach.
    Salomon L; Levrel O; Anastasiadis AG; Saint F; de La Taille A; Cicco A; Vordos D; Hoznek A; Chopin D; Abbou CC
    Prostate Cancer Prostatic Dis; 2002; 5(4):285-90. PubMed ID: 12627213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
    Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
    J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of residual prostate cancer after radical prostatectomy with the Abbott IMx PSA assay.
    Schild SE; Wong WW; Novicki DE; Ferrigni RG; Swanson SK
    Urology; 1996 Jun; 47(6):878-81. PubMed ID: 8677580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of positive surgical margin and biochemical recurrence of patients treated with radical prostatectomy: a single-center 10-year report.
    Li K; Li H; Yang Y; Ian LH; Pun WH; Ho SF
    Chin Med J (Engl); 2011 Apr; 124(7):1001-5. PubMed ID: 21542957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deoxyribonucleic acid ploidy and serum prostate specific antigen predict outcome following salvage prostatectomy for radiation refractory prostate cancer.
    Amling CL; Lerner SE; Martin SK; Slezak JM; Blute ML; Zincke H
    J Urol; 1999 Mar; 161(3):857-62; discussion 862-3. PubMed ID: 10022701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.